Sugi Predict

Sugi Predict / Compounds / SCHEMBL14656131

SCHEMBL14656131

SCHEMBL14656131

N#Cc1cc(C=O)ccc1Oc1ccc(F)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 11/20 0.51
▸ ESRRA P11474 1/20 0.45
▸ AR P10275 3/20 0.44
▸ KCNH2 Q12809 3/20 0.43
▸ HTR2A P28223 2/20 0.43
▸ SLC6A4 P31645 2/20 0.43
▸ EPAS1 Q99814 3/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C8 P10632 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ SLC22A6 Q4U2R8 1/20 0.43
▸ SLC22A8 Q8TCC7 1/20 0.43
▸ SLC22A11 Q9NSA0 1/20 0.43
▸ VEGFA P15692 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14656186 0.90 SLC22A12 (0.51) SLC22A12ESRRAARKCNH2HTR2A
SCHEMBL14656258 0.89 AR (0.55) SLC22A12ESRRAARKCNH2CYP3A4
SCHEMBL14656177 0.88 SLC22A12 (0.48) SLC22A12ESRRAAREPAS1VEGFA
SCHEMBL14661906 0.88 SLC22A12 (0.48) SLC22A12ESRRAAREPAS1VEGFA
SCHEMBL14662245 0.87 AR (0.50) SLC22A12ESRRAARKCNH2CYP3A4
SCHEMBL14656239 0.87 SLC22A12 (0.47) SLC22A12ESRRAAR
SCHEMBL14663584 0.85 PLA2G7 (0.47) SLC22A12ESRRAAR
SCHEMBL9889477 0.85 SLC22A12 (0.51) SLC22A12ESRRAARKCNH2HTR2A
SCHEMBL876294 0.84 AR (0.53) ESRRAAR
SCHEMBL14656430 0.84 HTR2A (0.46) KCNH2HTR2ASLC6A4EPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300965-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-12 — — US disclosed
US-11999746-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-06-04 — — US disclosed
US-20200055863-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-02-20 — — US disclosed
US-10428078-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-10-01 — — US disclosed
EP-3172211-B1 TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 GLAXOSMITHKLINE IP DEV LTD (GB) 2019-07-03 — — EP disclosed
US-20190023715-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-24 — — US disclosed
US-10125141-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-11-13 — — US disclosed
US-20170204109-A1 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-07-20 — — US disclosed
EP-3172211-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-05-31 — — EP disclosed
CN-103827116-B As LP-PLA2the 2,3-glyoxalidine of inhibitor also [1,2-c] pyrimidine-5 (1H)-one compound 葛兰素集团有限公司 2016-08-31 — — CN disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2014-06-26 — — US disclosed
EP-2739627-A1 2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA² INHIBITORS Glaxo Group Limited (GB) 2014-06-11 — — EP disclosed
EP-2736908-A1 BICYCLIC PYRIMIDONE COMPOUNDS Glaxo Group Limited (GB) 2014-06-04 — — EP disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — US disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — WO disclosed
WO-2013013503-A1 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-31 — — WO disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055863-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885
US-20140179716-A1 BICYCLIC PYRIMIDONE COMPOUNDS PLA2G7, PLA2G4A, PLA2G1B SLC22A12 3061/4885ESRRA 4814/4885AR 4584/4885
US-20190023715-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885
US-10125141-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885
US-10428078-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885
US-20240300965-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885
US-20130030012-A1 COMPOUNDS LPCAT1, PLA2G7, PLAAT2 SLC22A12 3088/4885ESRRA 4156/4885AR 4420/4885
US-11999746-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885
US-20170204109-A1 Compounds PLAAT2, PLA2G12A, PLA2G1B SLC22A12 3059/4885ESRRA 4402/4885AR 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.